David L. Porter, MD

New ASCO data comparing FACT-accredited and non-accredited centers show similar patients, similar toxicities, and similar infection rates, though Dr. Porter cautions the claims-based analysis carries real limitations.

Dr. Porter walks through how his health system built two community CAR T-cell therapy sites from scratch, matching academic-level quality before either earned formal FACT accreditation.

Dr. Porter distinguishes community-based CAR T-cell therapy from non-accredited care, describing why extending treatment beyond academic centers demands the same rigorous standards patients already expect.

Dr. Porter argues FACT accreditation's original rationale for CAR T-cell therapy still holds, even as the standards evolve to fit community programs without loosening quality or safety requirements.

Dr. Porter frames access as CAR T-cell therapy's central challenge, outlining the safety, efficacy, and affordability gains still needed before outpatient administration can meaningfully close the gap for patients.